Results 181 to 190 of about 965,759 (306)

RNA‐Binding Proteins Shape Mammalian Retroelement RNA Fate: Lessons From HIV‐1, LINE‐1, and Related Reverse‐Transcribing Elements

Animal Research and One Health, EarlyView.
RNA‐binding proteins (RBPs) and RNA‐associated factors shape retroelement RNA fate by regulating RNA processing, translation, RNP assembly and remodeling, reverse transcription, nuclear trafficking, chromatin engagement, and RNA surveillance. These pathways balance productive retroviral replication or retrotransposon insertion with RNA decay ...
Mingrui Li, Zhangyuan Pan, Yongjuan Guan
wiley   +1 more source

An optimized product-enhanced reverse transcriptase assay for sensitive and quantitative detection of HIV viral load and phenotypic drug resistance. [PDF]

J Clin Microbiol
Mims DK, Chang MM, Olanrewaju AO.
europepmc   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Coordinated RNA- and protein-templated synthesis of double-stranded DNA by a dual reverse transcriptase immune system. [PDF]

Cell
Wang M, Yoneyama K, Žedaveinytė R, Ishikawa J, Tang S, Le HC, Wiegand T, Ramirez JL, Nagahata N, Ma Y, Zhang DJ, Helmeczi E, Berisa M, Jovanovic M, Hiraizumi M, Yamashita K, Nishimasu H, Sternberg SH.   +17 more
europepmc   +1 more source

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule, Maryam Habib, Rija Khalid, Jessie Tu, Deborah Yoong, Jaris Swidrovich, Wale Ajiboye, Patrick O'Byrne, Ameeta E. Singh, Jean‐Guy Baril, Tatiana Sotindjo, Mark W. Hull, Darrell H. S. Tan   +12 more
wiley   +1 more source

Protein-templated synthesis of dinucleotide repeat DNA by an antiphage reverse transcriptase. [PDF]

Science
Deng P, Lee H, Armijo C, Wang H, Gao A.
europepmc   +1 more source

Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5‐year analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Careful consideration of drug–drug interactions (DDIs) is critical as people with HIV age. We analysed queries submitted to the University of Liverpool HIV Drug Interactions Database to assess changes in prescribing patterns over 5 years. Methods Queries submitted between January 2020 and December 2024 were extracted and categorized by year ...
Cecile Gras, Minh P. Le, Justin Chiong, Sara Gibbons, Daniel Seddon, Catia Marzolini, Saye Khoo   +6 more
wiley   +1 more source

Correction: A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. [PDF]

PLoS One
Imamura S, Uchiyama J, Koshimizu E, Hanai JI, Raftopoulou C, Murphey RD, Bayliss PE, Imai Y, Burns CE, Masutomi K, Gagos S, Zon LI, Roberts TM, Kishi S.   +13 more
europepmc   +1 more source

Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring

British Journal of Clinical Pharmacology, EarlyView.
Lenacapavir (LEN), a first‐in‐class capsid inhibitor, has unique pharmacokinetics that enable twice‐yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug–drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant ...
Aaron S. Devanathan, Thomas Glowa, Emily M. Thompson, Amanda J. Saylor, Thomas D. Nolin, Sharon A. Riddler, Ken S. Ho   +6 more
wiley   +1 more source

Anti-HIV Potential of <i>Origanum vulgare</i> Compounds Targeting Viral Reverse Transcriptase with High Binding and Stability Validated by Machine Learning. [PDF]

Viruses
Bajrai LH, Ghazali R.
europepmc   +1 more source